Nanotube Based POC Platform

Technology

Nanotechnology allows for the design and manufacture of complex multi-functional devices which could lead to the miniaturization of biological assays and POC platforms. Based on the advances in nanotechnology, BioMedomics is utilizing small highly conductive carbon-based nanotubes to develop a next generation platform which eliminates the need for labeling, membranes or any optical elements. This platform uses antibody-functionalized, carbon-nanotube field-effect transistor (FET) sensors coupled to lateral flow immunoassay technologies in which antibodies are attached to nanotubes and placed on biosensor strips allowing ultra-sensitive circuits to detect antibody attachment. This direct electronics detection eliminates many of the issues with fluorescent and optical detection, giving us enhanced sensitivity and selectivity while holding the potential for real-time and continous monitoring in a small, simple device similar to a Blood Glucose Monitor.

Development Efforts

Under an NIH SBIR grant, BioMedomics has developed a first generation nanotube-based platform. Utilizing this technology, we were able to detect the cardiovascular biomarker, C-reactive protein (CRP), at levels approaching 0.1 picogram/mL. The significant increase in specificity and sensitivity hold the potential for an earlier and more precise clinical diagnosis for recognizing diseases such as cancer, and can be used for post-treatment monitoring to detect recurrence of disease.

Applications

This universal detection platform also has the ability to be used in a broad range of non-clinical diagnostics applications including bio-defense, drug delivery and development, veterinary diagnostics, drugs-of-abuse testing, food safety tests and environmental monitoring.

BioMedomics, Inc.

1100 Perimeter Park Drive

Suite 104

Morrisville, NC 27560

USA

www.biomedomics.com

Tel: 919.890.3070

Email: info@biomedomics.com